MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
jamanetwork.com
·

HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse

HepB-CpG vaccine (2 or 3 doses) achieved superior HBV seroprotection in HIV-positive individuals with prior nonresponse to hepatitis B vaccine, compared to conventional HepB-alum vaccine (3 doses).
labiotech.eu
·

Trump's healthcare cabinet picks: Implications for U.S. biopharma

Trump's healthcare picks, including anti-vaccine activist Robert Kennedy Jr for HHS, spark debate. Kennedy's appointment led to health stock drops and vows to overhaul NIH and FDA. Other nominees include lockdown opponents Jay Bhattacharya for NIH, Dave Weldon for CDC, and Marty Makary for FDA. Celebrity doctor Mehmet Oz is tapped to lead CMS, and Fox News' Janette Nesheiwat is chosen for Surgeon General.
medicine.washu.edu
·

Probiotic delivers anticancer drug to the gut

Researchers at WashU Medicine engineered a yeast probiotic to deliver immunotherapy directly to the gut, shrinking gastrointestinal tumors in mice, offering a novel strategy for hard-to-reach gut cancers.
cnhinews.com
·

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell ...

Soligenix forms European Medical Advisory Board for HyBryte™ Phase 3 CTCL study, targeting 2024 initiation with 80 patients in US and Europe, aiming for 2026 results.
kilgorenewsherald.com
·

NIAID Exercises Option to Continue Preclinical Development of Bolder BioTechnology's BBT-059

Bolder BioTechnology announced NIAID's option to fund the second year of Contract NIH-BAA-75N93023C00011, focusing on BBT-059's advanced development as a radiation medical countermeasure. The contract aims to complete GMP manufacturing, preclinical safety studies, and enable an Investigational New Drug Application filing with the FDA, totaling $3,079,369.
finance.yahoo.com
·

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of ...

Soligenix opens patient enrollment for Phase 2 study DUS-AUBD-01 evaluating SGX945 (dusquetide) for Behçet's Disease, aiming to address significant unmet medical needs.
markets.ft.com
·

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment

Soligenix opens patient enrollment for Phase 2 study DUS-AUBD-01, evaluating SGX945 (dusquetide) for Behçet's Disease treatment.
ualberta.ca
·

ATI-NIAID International Symposium

International symposium on “Systems Immunology in Transplantation: Advances, Challenges, and Opportunities” co-hosted by Alberta Transplant Institute and NIAID, March 27-28, 2025, in Edmonton. Focuses on leveraging systems immunology technologies to address transplantation challenges.
© Copyright 2025. All Rights Reserved by MedPath